RDHL
RedHill Biopharma Ltd.
NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic · IL
$0.39
−6.91%Price chart
Oct 1Oct 6Oct 9Oct 14Oct 19Oct 22Oct 27Oct 30
Key dataOct 30, 2026
Open$0.39
From 52W high−72.30%
Volume108889.00
Market cap$3.45M
P/E (TTM)—
P/S (TTM)12.1x
Div yield—
Key dataOct 30, 2026
Open
$0.39
From 52W high
−72.30%
Volume
108889.00
Market cap
$3.45M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−0.1x
P/E (TTM)
—
RSI (14)
34.5
MomentumView details →
1D Return
−6.91%
YTD Return
−61.66%
SummaryUpdated Dec 1, 2025
RedHill Biopharma Ltd. (NASDAQ:RDHL) is a specialty biopharmaceutical company founded in 2009 and headquartered in Tel Aviv, Israel. The company went public in 2013 and focuses primarily on developing and commercializing treatments for gastrointestinal and infectious diseases. RedHill operates as a clinical-stage biopharmaceutical company with a portfolio of marketed products and an extensive pipeline of investigational drugs in various stages of development.
Similar companies
Latest newsMore news →
RedHill Biopharma Ltd. received a $2.9 million National Cancer Institute grant to support clinical development of opaganib combined with CAR T-cell therapy for ultra-high-risk multiple myeloma.11d agoRedHill Biopharma reported its first half 2026 financial results alongside operational highlights, including its reset portfolio of Rebyota and Clenpiq, which generated $37.5 million in 2025 net sales under Ferring Pharmaceuticals.30d agoRedHill acquired global commercialization rights to Ferring's Rebyota and Clenpiq.58d ago